This year, results have been published of two significant research studies about molecules that could potentially be used to treat Alzheimer's disease. The chief researcher in both studies was Dr. Yan Ivanenkov, the head of the Laboratory of Medical Chemistry and Bioinformatics at the Moscow Institute of Physics and Technology (MIPT). Papers on the two new molecules were published in Molecular Pharmaceutics and Current Alzheimer Research. Mark Veselov, another MIPT researcher, also participated in the second study. Both papers cover the study of neuroprotectors - antagonists to the 5-HT6R receptor. The latest research confirms that this target has a high therapeutic potential in the treatment of Alzheimer's disease. Preclinical studies on lab animals have shown that the two studied compounds have a high selectivity. Alzheimer's is one of the most widespread diseases in elderly people. People over the age of 60 are at the greatest risk of developing the disease, but it can also occur at a younger age. Patients suffer from loss of memory and cognitive functions; they become socially detached and lose their independence, and the body can no longer function properly, which inevitably leads to death. According to medical statistics, Alzheimer's is the cause of two out of every three cases of dementia in the elderly and it is a huge economic problem in developed countries. Scientists have not yet succeeded in finding an effective cure for Alzheimer's. Despite the fact that we know much about how the disease develops, we cannot say that we are even close to a solution. Pharmaceutical studies are still being conducted in order to be able to reduce the symptoms of the disease. In the first paper, specialists Alexander Ivashenko and Yan Lavrovsky from Alla Chem LLC, Avineuro Pharmaceuticals Inc., and R-Pharm Overseas Inc.
Login Or Register To Read Full Story